October 13th, 2023

Lululemon Athletica Inc. (Nasdaq: LULU), a notable athletic apparel company, will replace Activision Blizzard Inc. (Nasdaq: ATVI) in the S&P 500 index, effective at the opening of trading on Wednesday, October 18. The S&P 500 is widely recognized . Read more

September 27th, 2023

UBS has initiated coverage on Blink Charging Co. (Nasdaq: BLNK), a leading provider of electric vehicle charging services, with a Buy rating and a price target of $7. With $BLNK closing at $2.93 on Tuesday, the price target suggests a significant . Read more

July 28th, 2023

Multiple companies are set to report their financial results on Tuesday, August 1, including: Merck & Co., Inc. (NYSE: MRK), a pharmaceutical giant, is expected to announce its second-quarter 2023 earnings results prior to the market opening. . Read more

July 15th, 2023

Seagen Inc. (Nasdaq: SGEN) and Pfizer Inc. (NYSE: PFE) have encountered a regulatory hurdle in their planned merger. According to a regulatory filing with the SEC, both companies received a Second Request from the Federal Trade Commission (FTC) on Ju. Read more

July 06th, 2023

Shares of Mullen Automotive, Inc. (Nasdaq: MULN) surged over 60% in pre-market trading after the company announced a $25 million stock buyback program authorized through December 31, 2023. Mullen believes that its stock is significantly undervalue. Read more

June 29th, 2023

Employee and friend traded ahead of Pfizer’s “game-changer” announcement on the success of its Paxlovid trial FOR IMMEDIATE RELEASE 2022-123 Washington D.C. / CRWE PRESS RELEASE / June 29, 2023 -  The Securities and Exch. Read more

June 28th, 2023

Pfizer Inc. (NYSE: PFE) and  OPKO Health Inc. (Nasdaq: OPK) said that the  U.S. Food and Drug Administration  (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly treatment for pediatric patients with growth hormone deficiency (G. Read more

June 25th, 2023

Pfizer Inc. (NYSE: PFE) has received FDA approval for LITFULO (ritlecitinib), an oral treatment for severe alopecia areata in individuals aged 12 and above. LITFULO, which is expected to be available in the coming weeks, is the first and only FDA-app. Read more

June 21st, 2023

argenx SE (Nasdaq: ARGX) has received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo, a subcutaneous injection used to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine. Read more

June 20th, 2023

Shares of Sanofi (Nasdaq: SNY) surged in pre-market trading following the announcement of a favorable outcome in an International Chamber of Commerce dispute.  The tribunal ruled in favor of Sanofi, dismissing Boehringer Ingelheim's. Read more

June 09th, 2023

Theravance Biopharma Ireland Limited, an affiliate of Theravance Biopharma, Inc. (Nasdaq: TBPH), entered into a global license agreement with Pfizer Inc. (NYSE: PFE) in December 2019 for its preclinical skin-selective, locally acting pan-JAK inhibito. Read more

June 01st, 2023

Pfizer Inc. (NYSE: PFE), a global pharmaceutical company specializing in vaccines and medicines, announced that its bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO, has received approval from the U.S. Food and Drug Administration (FDA).  . Read more

May 19th, 2023

CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more

May 18th, 2023

Ross Stores, Inc. (Nasdaq: ROST) has reported first-quarter fiscal 2023 earnings per share (EPS) of $1.09, surpassing the consensus estimate of $1.06. However, in after-hours trading, $ROST is experiencing a slight decline, currently trading at $105.. Read more